Unveiling the therapeutic potential of ketamine in depression: A bibliometric analysis and research landscape overview

HTML Full Text

Reference

1. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva, Switzerland: World Health Organization; 2017.
2. Vuyk J, Sitsen E, Reekers M. Intravenous anesthetics. In: Miller R, editor. Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 858.
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4. https://doi.org/10.1016/S0006-3223(99)00230-9
4. Salahudeen MS, Wright CM, Peterson GM. Esketamine: new hope for the treatment of treatment-resistant depression? a narrative review. Ther Adv Drug Saf. 2020;11:2042098620937899. https://doi.org/10.1177/2042098620937899
5. Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay MA, Baker GB, et al. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020;10:2045125320916657. https://doi.org/10.1177/2045125320916657
6. Li X, Xiang P, Liang J, Deng Y, Du J. Global trends and hotspots in esketamine research: a bibliometric analysis of past and estimation of future trends. Drug Des Devel Ther. 2022;16:1131-42. https://doi.org/10.2147/DDDT.S356284
7. Miao H, Yu K, Gao D, Lin X, Cao Y, Liu X, et al. A bibliometric analysis of research on ketamine from 2001 to 2020. Front Mol Neurosci. 2022;15:839198. https://doi.org/10.3389/fnmol.2022.839198
8. Harzing AW. The publish or perish book. Melbourne, Australia: Tarma Software Research Pty Limited; 2010.
9. Van Eck NV, Waltman L. VOSviewer manual-Manual for VOSviewer version 1.6. 17. Leiden, Netherlands: Universiteit Leiden; 2021.
10. Zakaria WNA, Sasongko TH, Al-Rahbi B, Al-Sowayan N, Ahmad AH, Zakaria R, et al. Gene and schizophrenia in the pregenome and postgenome-wide association studies era: a bibliometric analysis and network visualization. Psychiatr Genet. 2023;33(2):37-49. https://doi.org/10.1097/YPG.0000000000000336
11. Zakaria R, Ahmi A, Ahmad AH, Othman Z, Azman KF, Ab Aziz CB, et al. Visualising and mapping a decade of literature on honey research: a bibliometric analysis from 2011 to 2020. J Apic Res. 2021;60(3):359-68. https://doi.org/10.1080/00218839.2021.1898789
12. Duan L, Gao Y, Shao X, Tian C, Fu C, Zhu G. Research on the development of theme trends and changes of knowledge structures of drug therapy studies on major depressive disorder since the 21st century: a bibliometric analysis. Front Psychiatry. 2020;11:647. https://doi.org/10.3389/fpsyt.2020.00647
13. Mischel NA, Balon R. Esketamine: a drug to treat resistant depression that brings more questions than answers. J Clin Psychopharmacol. 2021;41(3):233. https://doi.org/10.1097/JCP.0000000000001395
14. Yavi M, Lee H, Henter ID, Park LT, Zarate Jr CA. Ketamine treatment for depression: a review. Discov Ment Health. 2022;2(1):9. https://doi.org/10.1007/s44192-022-00012-3
15. Goldberg JF. Ketamine and cognitive function in depression: detrimental, neutral, or advantageous? J Clin Psychiatry. 2022;83(1):38970. https://doi.org/10.4088/JCP.21com14243
16. Zhang JC, Yao W, Hashimoto K. Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology. 2022;218:109219. https://doi.org/10.1016/j.neuropharm.2022.109219
17. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-6. https://doi.org/10.1016/j.biopsych.2012.06.022
18. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139-48. https://doi.org/10.1001/jamapsychiatry.2017.3739
19. Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554(7692):317-22. https://doi.org/10.1038/nature25509
20. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522-6. https://doi.org/10.1016/j.biopsych.2009.04.029
21. Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-45. https://doi.org/10.1016/j.biopsych.2009.08.038
22. Zarate Jr CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-46. https://doi.org/10.1016/j.biopsych.2011.12.010
23. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970-6. https://doi.org/10.1016/j.biopsych.2014.03.026
24. Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014;155:123-9. https://doi.org/10.1016/j.jad.2013.10.036
25. Bahji A, Vazquez GH, CA Zarate Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542-55. https://doi.org/10.1016/j.jad.2020.09.071
26. Bartoli F, Wlkinson ST. Ketamine and esketamine for suicidal ideation: recent progress and practical issues. Aust NZJ Psychiatry. 2020;54(2):206-7. https://doi.org/10.1177/0004867419894064
27. Lee Y, Syeda K, Maruschak NA, Cha DS, Mansur RB, Wium-Andersen IK, et al. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. J Clin Psychopharmacol. 2016;36(1):50-6. https://doi.org/10.1097/JCP.0000000000000441
28. Gill H, Gill B, Rodrigues NB, Lipsitz O, Rosenblat JD, El-Halabi S, et al. The effects of ketamine on cognition in treatment-resistantdepression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021;120:78-85. https://doi.org/10.1016/j.neubiorev.2020.11.020
29. Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805-13. https://doi.org/10.1017/S1461145714001011
30. Liu W, Zhou Y, Zheng W, Wang C, Zhan Y, Lan X, et al. Repeated intravenous infusions of ketamine: neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord. 2019;259:1-6. https://doi.org/10.1016/j.jad.2019.08.012
31. Zanos P, Gould T. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801-11. https://doi.org/10.1038/mp.2017.255
32. Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81(10):88697. https://doi.org/10.1016/j.biopsych.2016.05.005
33. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci. 2017;42(4):222-9. https://doi.org/10.1503/jpn.160175
34. Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. Ketamine's mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety. 2016;33(8):689-97. https://doi.org/10.1002/da.22501
35. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014;29(7):419-23. https://doi.org/10.1016/j.eurpsy.2013.10.005
36. Du J, Machado-Vieira R, Maeng S, Martinowich K, Manji HK, Zarate Jr CA. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov. Today Ther Strateg. 2006;3(4):519-26. https://doi.org/10.1016/j.ddstr.2006.11.012
37. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349-52. https://doi.org/10.1016/j.biopsych.2007.05.028
38. Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K. Ketamine and its metabolite (2R, 6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry. 2018;23(10):2066-77. https://doi.org/10.1038/mp.2017.239
39. Skiteva O, Yao N, Chergui K. Ketamine induces opposite changes in AMPA receptor calcium permeability in the ventral tegmental area and nucleus accumbens. Transl Psychiatry. 2021;11(1):530. https://doi.org/10.1038/s41398-021-01658-3
40. Trujillo KA. The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. Neurotox Res. 2002;4(4):373-91. https://doi.org/10.1080/10298420290023954
41. Glass MJ, Vanyo L, Quimson L, Pickel VM. Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala. Neuroscience. 2009;163(3):857-67. https://doi.org/10.1016/j.neuroscience.2009.07.020
42. Chartoff EH, Connery HS. It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol. 2014;5:116. https://doi.org/10.3389/fphar.2014.00116
43. Borsini A, Di Benedetto MG, Giacobbe J, Pariante CM. Pro-And anti-inflammatory properties of interleukin in vitro: relevance for major depression and human hippocampal neurogenesis. Int J Neuropsychopharmacol. 2020;23(11):738-50. https://doi.org/10.1093/ijnp/pyaa055
44. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-9. https://doi.org/10.1016/j.bbi.2020.02.010
45. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31. https://doi.org/10.1016/j.it.2005.11.006
46. Rosenblat JD, ChaDS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry.2014;53:23-34. https://doi.org/10.1016/j.pnpbp.2014.01.013
47. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression--And other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett. 2007;28(6):826-31.
48. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81(4):247-65. https://doi.org/10.1046/j.1440-1711.2003.t01-1-01177.x
49. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199-229. https://doi.org/10.1016/j.neuroscience.2013.04.060
50. Nikkheslat N, McLaughlin AP, Hastings C, Zajkowska Z, Nettis MA, Mariani N, et al. Childhood trauma, HPA axis activity and antidepressant response in patients with depression. Brain Behav Immun. 2020;87:229-37. https://doi.org/10.1016/j.bbi.2019.11.024
51. Nikkheslat N, Pariante CM, Zunszain PA. Neuroendocrine abnormalities in major depression: an insight into glucocorticoids, cytokines, and the kynurenine pathway. In: Baune, BT, editor. Inflammation and immunity in depression. Cambridge, MA: Academic Press; 2018. pp. 45-60. https://doi.org/10.1016/B978-0-12-811073-7.00003-9
52. Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry. 2015;72(6):603-11. https://doi.org/10.1001/jamapsychiatry.2015.0071
53. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1-38. https://doi.org/10.1196/annals.1440.011
54. Buckner RL, DiNicola LM. The brain's default network: updated anatomy, physiology and evolving insights. Nat Rev Neurosci. 2019;20(10):593-608. https://doi.org/10.1038/s41583-019-0212-7
55. Scalabrini A, Vai B, Poletti S, Damiani S, Mucci C, Colombo C, et al. All roads lead to the default-mode network-global source of DMN abnormalities in major depressive disorder. Neuropsychopharmacology. 2020;45(12):2058-69. https://doi.org/10.1038/s41386-020-0785-x
56. Scheidegger M, Walter M, Lehmann M, Metzge, C, Grimm S, Boeker H, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012;7(9):e44799. https://doi.org/10.1371/journal.pone.0044799
57. Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci USA. 2010;107(24):11020-5. https://doi.org/10.1073/pnas.1000446107
58. Li J, Chen J, Kong W, Li X, Hu B. Abnormal core functional connectivity on the pathology of MDD and antidepressant treatment: a systematic review. J Affect Disord. 2022;296:622-34. https://doi.org/10.1016/j.jad.2021.09.074
59. Krug S, Müller T, Kayali Ö, Leichter E, Peschel SKV, Jahn N, et al. Altered functional connectivity in common resting-state networks in patients with major depressive disorder: a resting-state functional connectivity study. J Psychiatr Res. 2022;155:33-41. https://doi.org/10.1016/j.jpsychires.2022.07.040
60. W?odarczyk A, Cuba?a WJ. Safety and tolerability of ketamine use in treatment-resistant bipolar depression patients with regard to central nervous system symptomatology: literature review and analysis. Medicina. 2020;56(2):67. https://doi.org/10.3390/medicina56020067
61. Smith-Apeldoorn SY, Vischjager M, Veraart JK, Kamphuis J, Aan Het Rot M, Schoevers, RA. The antidepressant effect and safety of non-intranasal esketamine: a systematic review. J Psychopharmacol. 2022;36(5):531-44. https://doi.org/10.1177/02698811221084055
62. Dilip TS, Chandy G.M, Hazra D, Selvan J, Ganesan P. The adverse effects of ketamine on procedural sedation and analgesia (PSA) in the emergency department. J Family Med Prim Care. 2021;10(6):2279. https://doi.org/10.4103/jfmpc.jfmpc_2140_20
63. D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, et al. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry. 2012;72(9):785-94. https://doi.org/10.1016/j.biopsych.2012.05.009
64. Drug Enforcement Administration (DEA). Drug fact sheet: ketamine. 2020. Available from https://www.dea.gov/sites/default/files/2020-06/Ketamine-2020.pdf
65. Kleczkowska P, Zaremba M. An update of ketamine illicit use. IntechOpen; 2022. https://doi.org/10.5772/intechopen.100644
66. Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, et al. Suicide prevention strategies: a systematic review. JAMA. 2005;294(16):2064-74. https://doi.org/10.1001/jama.294.16.2064
67. Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362-7. https://doi.org/10.1016/j.jad.2018.04.016
68. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150-8. https://doi.org/10.1176/appi.ajp.2017.17040472
69. Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust NZJ Psychiatry. 2020;54(1):29-45. https://doi.org/10.1177/0004867419883341
70. Chen CC, Zhou N, Hu N, Feng JG, Wang XB. Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2023;9:587-99. https://doi.org/10.2147/NDT.S401032

Article Metrics

Similar Articles

Related Search

By author names

Omar N [PubMed] [Google Scholar ]
Othman Z [PubMed] [Google Scholar ]
Halim A S A [PubMed] [Google Scholar ]
Ahmad R [PubMed] [Google Scholar ]
Md M R M L [PubMed] [Google Scholar ]
Shafin N [PubMed] [Google Scholar ]
Ahmad A H [PubMed] [Google Scholar ]
R Z [PubMed] [Google Scholar ]